10-Q/A: REMSleep Holdings Restates Q1 2024 Report Due to Share Count Error, Cites Ongoing Going Concern Issues

REMSleep Holdings has filed an amended 10-Q report for the quarter ended March 31, 2024, to correct the number of outstanding shares, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.

Summary

• REMSleep Holdings has restated its Form 10-Q for the quarter ended March 31, 2024, solely to correct the number of outstanding shares on the cover page.
• The company's net loss for the quarter was $252,580, compared to a net loss of $226,259 for the same period last year.
• Revenue decreased to $57,881 from $85,655 in the prior year's quarter, primarily due to fewer sales and fewer multiple unit sales.
• Operating expenses decreased to $168,506 from $233,055, with reductions in professional fees, compensation, and lease expenses.
• The company's cash balance was $730,625 as of March 31, 2024, compared to $719,100 at the end of 2023.
• A convertible note payable of $143,000 was issued on January 10, 2024, with a 10% interest rate and a conversion option after 180 days.
• The company has an accumulated deficit of $14,445,339 and has used $113,475 in operating activities for the quarter.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
• The company is working towards FDA approval for its DeltaWave product, expected by the third quarter of 2024.
• Subsequent to the quarter end, the company sold 13,696,484 shares of common stock for $70,000.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including increased losses, decreased revenue, and substantial doubt about the company's ability to continue as a going concern. While there are some positive aspects, such as cost-cutting and progress towards FDA approval, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• Operating expenses decreased by $64,549 year-over-year, indicating cost-cutting measures.
• The company secured $125,000 in financing through a convertible note payable.
• The company is progressing towards FDA approval for its DeltaWave product, which is expected in the third quarter of 2024.

Negatives

• The company reported a net loss of $252,580 for the quarter, an increase from the $226,259 loss in the same period last year.
• Revenue decreased to $57,881, a significant drop from $85,655 in the prior year's quarter.
• The company has an accumulated deficit of $14,445,339.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of segregation of duties.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• The company's revenue has decreased, indicating potential challenges in sales and market acceptance.
• The company's reliance on debt and equity financing may not be sustainable in the long term.
• The company's internal controls are not effective, which could lead to financial reporting issues.
• Delays in FDA approval for the DeltaWave product could further impact the company's financial position.

Future Outlook

The company plans to continue financing operations through debt and/or equity financing as needed and expects FDA approval for its DeltaWave product by the third quarter of 2024. The company's future success is dependent on its ability to generate capital financing and increase profitability.

Management Comments

• Management believes that the DeltaWave is designed to effectively address issues that affect a patient's ability to comply with sleep apnea treatment.
• Management is working to resolve issues with the cytotoxicity test for the DeltaWave product.
• Management plans to obtain funding from new investors to alleviate the working capital deficiency and implement a plan to generate sales.

Industry Context

The company operates in the competitive sleep apnea device market, where mask comfort and compliance are key concerns. The company's focus on the DeltaWave product, designed for improved comfort and breathing mechanics, aligns with industry trends towards patient-centric solutions. The company faces competition from larger, better-capitalized companies in the industry.

Comparison to Industry Standards

• The company's revenue of $57,881 for the quarter is significantly lower than established medical device companies, which often report revenues in the millions or billions.
• The net loss of $252,580 is typical for early-stage companies in the medical device sector, but the company's going concern issues are a significant concern.
• The company's reliance on convertible debt is a common financing strategy for early-stage companies, but the high interest rate of 10% and the potential for dilution are risks.
• The company's focus on a novel nasal-pillows interface is similar to other companies in the sleep apnea market that are trying to improve patient comfort and compliance, such as ResMed and Philips Respironics, but these companies have significantly more resources and market share.
• The company's timeline for FDA approval of the DeltaWave product is consistent with the regulatory process for medical devices, but delays in testing and approval are not uncommon.

Management Changes

Related Party Transactions

• The company has an employment agreement with Mr. Wood, with accrued compensation of $14,500 as of March 31, 2024.
• The company has accrued compensation of $46,000 due to Russell Bird, the former Chairman, as of March 31, 2024.
• The company made payments to the brother of the CEO for services related to product development.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues and potential dilution from future capital raises.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers may be affected by potential delays in product development and availability.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to seek debt and/or equity financing.
• The company will complete testing for the DeltaWave product and submit the 510k application to the FDA.
• The company will implement a plan to generate sales.

Key Dates

Keywords

REMSleep Holdings, sleep apnea, CPAP, DeltaWave, financial results, going concern, convertible note, FDA approval, restatement, share count